Advanced Accelerator Applications USA Inc
Advanced Accelerator Applications USA Inc received −$9.3M in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 401.5% from $3.1M the year before, and $67.6M since FY2022. Its largest customer is the Department of Veterans Affairs.
See 4 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- JNM4NBNHFE66
- CAGE code
- 3PTH3
- Headquarters
- New York, NY
- Business size
- Small Business
- Parent company
- Novartis AG (UEI F6FZK4X6JT21)
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Veterans Affairs | −$9.1M | $56.5M |
| Department of Defense | $0 | $11.2M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $66.6M |
| 6550 | In Vitro Diagnostic Substances, Reagents, Test Kits and Sets | $2.1M |
| 6515 | Medical and Surgical Instruments, Equipment, and Supplies | $158K |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 36C24926N0263 | Department of Veterans Affairs VISN PADIOPHARMACEUTICAL PLUVICTO DRUG | $892K | Dec 19, 2026 |
| 36C26026N0121 | Department of Veterans Affairs RADIOPHARMACEUTICALS: LUTETIUM LU 177 PLUVICTO 27MCI/ML. | $997K | Dec 31, 2026 |
| 36C25526N0132 | Department of Veterans Affairs PLUVICTO AND LUTATHERA | $1.2M | Feb 16, 2027 |
| 36C24927N0149 | Department of Veterans Affairs VISN PADIOPHARMACEUTICAL PLUVICTO DRUG | $960K | Sep 30, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 36C24927N0149 | Department of Veterans Affairs VISN PADIOPHARMACEUTICAL PLUVICTO DRUG | $960K | Oct 1, 2026 |
| 36C25526N0132 | Department of Veterans Affairs PLUVICTO AND LUTATHERA | $1.2M | Jan 13, 2026 |
| 36C26026N0121 | Department of Veterans Affairs RADIOPHARMACEUTICALS: LUTETIUM LU 177 PLUVICTO 27MCI/ML. | $997K | Dec 19, 2025 |
| 36C24926N0263 | Department of Veterans Affairs VISN PADIOPHARMACEUTICAL PLUVICTO DRUG | $2.4M | Dec 16, 2025 |
| HT001425P0095 | Department of Defense LUTATHERA LUTETIUM A RADIOACTIVE DRUG USED TO TREAT SOMATOSTATIN FOR WALTER REED. | $212K | May 13, 2025 |
| 36C25525N0282 | Department of Veterans Affairs PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN) EXTENSION | $266K | Apr 21, 2025 |
| 36C25525N0176 | Department of Veterans Affairs PLUVICTO AND LUTATHERA | $1.2M | Feb 17, 2025 |
| 36C25225F0044 | Department of Veterans Affairs PURCHASE OF MEDICATION ON AN 'AS-NEEDED' BASIS FOR 8 MONTHS. | $731K | Jan 2, 2025 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.